Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open-label Exploratory Trial
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Pityriasis rubra pilaris
- Focus Therapeutic Use
- 05 Nov 2019 Planned End Date changed from 15 Apr 2020 to 1 Jan 2020.
- 05 Nov 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Jan 2020.
- 05 Nov 2019 Status has been changed to recruiting.